Indian healthcare company Zydus Cadila has entered an exclusive agreement with Pharm Aid for the technology expertise of varicella vaccine production in Russia to prevent chickenpox.

Headquartered in Russia, Pharm Aid has been established by Nacimbio and Ishvan Pharmaceuticals for the localisation of new vaccine production in the country.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Zydus Cadila managing director Dr Sharvil Patel said: “As an innovation-driven global healthcare player our aim has always been to bridge unmet healthcare needs by improving accessibility to preventives and novel therapies.

“By being a technology enabler, I believe we are taking yet another important step in realising this mission.”

"By being a technology enabler, I believe we are taking yet another important step in realising this mission."

Pharm Aid director general Kirill Ganin added: “With the co-operation that will bring together partners’ experience, our local manufacturing, distribution and managerial capabilities, we will be able to reduce prime cost of the purchased vaccines and offer the market entirely new better medical products.”

Under the agreement, Zydus Cadila will gain access to the public and private market segments in the Russian Federation, Belarus, Uzbekistan, Kazakhstan, Armenia and Kyrgyzstan. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The new deal focuses on ensuring a continuous supply of varicella vaccines that can be included in the critical childhood immunisation programme.

The National Immunisation Programme does not feature this vaccine due to a lack of assured supply of indigenously manufactured varicella vaccine.

The demand for the vaccine is currently estimated at three million doses each year in the Russian Federation alone.